Burning Rock Biotech Limited is a cancer diagnostics company that provides next-generation sequencing (NGS)-based testing services to support precision medicine in oncology, primarily across China. The company's core offering is cancer therapy selection testing, which helps physicians identify targeted therapies and immunotherapies matched to individual patients' tumors; it also offers minimal residual disease (MRD) detection products to monitor patients for recurrence and is developing early cancer detection blood tests. Burning Rock operates through a central laboratory model where it processes patient samples for hospitals and physicians, and through an in-hospital partnership model where hospitals use the company's reagent kits in their own facilities, with revenues derived from test orders and reagent sales in both channels.